TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Annexon Biosciences ( (ANNX) ) has issued an update.
On November 12, 2025, Annexon, Inc. announced an underwritten public offering of 25,096,153 shares of common stock and 3,750,000 pre-funded warrants, raising approximately $80.4 million after expenses. The offering, managed by Goldman Sachs, TD Securities, and Wells Fargo, closed on November 14, 2025, with the underwriters exercising their option to purchase additional shares, indicating strong market interest and potentially enhancing Annexon’s financial position for future developments.
The most recent analyst rating on (ANNX) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Annexon Biosciences stock, see the ANNX Stock Forecast page.
Spark’s Take on ANNX Stock
According to Spark, TipRanks’ AI Analyst, ANNX is a Underperform.
Annexon Biosciences faces significant challenges typical of pre-revenue biotechnology companies. The lack of revenue and increasing financial losses are major concerns, despite strong cash reserves and low debt. Technical analysis indicates a bearish trend, and valuation metrics reflect the absence of profitability. Overall, the stock’s performance is constrained by financial and market challenges in a high-risk sector.
To see Spark’s full report on ANNX stock, click here.
More about Annexon Biosciences
Annexon, Inc. is a biopharmaceutical company focused on developing complement inhibitors to treat neuroinflammatory diseases affecting the body, brain, and eye. Their approach targets the C1q molecule to prevent the inflammatory cascade, addressing unmet needs in autoimmunity, neurodegeneration, and ophthalmology, potentially benefiting nearly 10 million people worldwide.
Average Trading Volume: 1,945,748
Technical Sentiment Signal: Sell
Current Market Cap: $312.1M
Find detailed analytics on ANNX stock on TipRanks’ Stock Analysis page.